Delivery Order SPE2DX15D2010-SPE2DX24F5TA2
- Not listed
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,885.36, is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of January 9, 2024 and is a Firm Fixed Price Delivery Order. This award is part of a larger Indefinite Delivery Contract (IDC) that...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,048.66, is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a completion date of November 6, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen...
- This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,571.91 firm fixed-price delivery order is for the supply of 4566804087 - DUPIXENT 300 MG/2 ML PEN 2ML. The contract has an ultimate completion date of December 30, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA...
- This federal contract award, valued at $14,326.77, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical product, with a firm fixed price and an ultimate completion date of July 16, 2025. The contract is not set-aside and is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,276.86 firm-fixed-price delivery order is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of November 14, 2024. The award is associated with a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support...
- This federal contract award, valued at $8,933.69, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, with a performance period through March 18, 2025. The award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999...
- This federal contract award, valued at $100,378.46, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a medical product, with an ultimate completion date of January 7, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,949.31, is a Delivery Order with a Firm Fixed Price pricing type. The contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product. The contract has an ultimate completion date of April 9, 2025. The award is part of a larger Indefinite Delivery Contract (IDC) that...
- This federal contract award, valued at $1,709.46, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a total potential value of $999,999,999 and runs through November 2026. The contract covers the procurement of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, to...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $83,527.15, is a delivery order for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a medical product. The contract has an ultimate completion date of January 28, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the...
- SPE2DX15D2010Indefinite Delivery Contract
- SPE2DX15D2010-SPE2DX24F5TA2Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,141.53, is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of October 24, 2023 and was awarded on October 23, 2023. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and Cencora, Inc., the parent company of Amerisourcebergen Drug Corp. This IDC, valued at up to $999,999,999.00, serves as the primary vehicle for Cencora, Inc. to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.1k | 10/23/23 |